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Abstract 
Hepatic stellate cells (HSCs) are considered as a major player in pathogeneses of hepatic fibrosis 
because they undergo a trans-differentiation into myofibroblastic cells termed “activation’’ in 
response to fibrogenic stimuli and produce excessive extracellular matrix (ECM). The characteristics 
of activated HSCs also include the active proliferation. Type I interferons (IFNs), generally applied 
for the therapy of eradication of hepatitis B and C viruses, were shown to have direct action on 
HSCs and suppress the activation, proliferation and production of ECM of HSCs. But the detailed 
molecular mechanisms of these effects of IFNs remain to be clarified. In this study, 
miRNAs-mediated action mechanisms of Type I IFNs for HSCs are investigated. 
First, the effect of miR-29b, which was previously identified as IFN-inducible miRNA and 
mediated the suppressive effect of IFNs on ECM production, on activation and proliferation of HSCs 
was investigated. miR-29b was found to be down-regulated during culture in primary mouse HSCs. 
Overexpression of miR-29b blunted the increased expression of key genes such as α-SMA involved 
in the activation of HSCs, and led HSCs to remain in a quiescent state as evidenced by their 
quiescent star-like cell morphology. Overexpression of miR-29b also inhibited the cell proliferation 
in primary HSCs and human HSC line LX-2. 
Furthermore, I identified miR-195 as a new IFN-responsible miRNA and investigated the effect 
on the proliferation of HSCs. miR-195 was prominently down-regulated in the proliferative phase of 
primary-cultured mouse HSCs. Supporting this fact, IFN-β induced miR-195 expression and 
inhibited the cell proliferation by delaying their G1 to S phase cell cycle progression in LX-2 cells. 
IFN-β down-regulated cyclin E1 and up-regulated p21 mRNA levels in LX-2 cells. Luciferase 
reporter assay revealed the direct interaction of miR-195 with the cyclin E1 3’ UTR. Overexpression 
of miR-195 lowered cyclin E1 mRNA and protein expression levels, increased p21 mRNA and 
protein expression levels, and inhibited cell proliferation in LX-2 cells. Moreover miR-195 
inhibition restored cyclin E1 levels that were down-regulated by IFN-β.  
In conclusion, these observations revealed new action mechanisms of type I IFNs for HSCs. Type 
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I IFNs induced miR-29b and miR-195. The miR-29b was involved in the suppressive effect of IFNs 
on activation, proliferation and excess ECM production in HSCs and the miR-195 was involved in 
the antiproliferative effect of IFNs in HSCs.  
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Abbreviations 
BSA:  bovine serum albumin 
CDK:  cyclin-dependent kinase 
Col1a1:  alpha 1 (I) collagen 
Col1a2:  alpha 2 (I) collagen 
DDR:  discoidin domain receptor 
DAPI:  40,6-diamidino-2-phenylindole 
DMEM:  Dulbecco’s modified Eagle’s medium 
ECM:  extracellular matrix 
ERK:  extracellular signal-regulated kinase 
FAK:  focal adhesion kinase 
FBS:  fetal bovine serum 
FN:  fibronectin 
GAPDH:  glyceraldehyde-3-phosphate dehydrogenase 
HCC:  hepatocellular carcinoma 
HSC:  hepatic stellate cell 
IFN:  interferon 
IFNAR:  type I interferon receptor 
ITGB1:  integrin β1 
miRNA:  microRNA 
PBS:  phosphate buffered saline 
PDGFR-β: platelet-derived growth factor receptor-β 
PI3K:  phosphatidylinositol-3 kinase 
SDS:  sodium dodecyl sulfate 
α-SMA:  α-smooth muscle actin 
STAT:  signal transducer and activator of transcription 
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TGF-β:  transforming growth factor-β 
3’UTR:  3’ untranslated region 
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General Introduction 
Hepatic fibrosis occurs through the imbalance of wound healing and is characterized by excessive 
accumulation of extracellular matrices (ECM). This is a common feature of chronic liver diseases 
such as chronic viral hepatitis, alcoholic hepatitis and non-alcoholic steatohepatitis (NASH), which 
lead to hepatic cirrhosis and finally to hepatic carcinoma. But there are no drugs whose mechanism 
is based on the prevention of progress of fibrosis at present. Hepatic stellate cells (HSCs) are 
considered to play principal role in the fibrotic process. HSCs are located in the Disse space between 
hepatocytes and sinusoidal endothelial cells and surround the sinusoidal vessel. Under physiological 
conditions, HSCs maintain a quiescent phenotype. They store vitamin A and release it into blood 
vessel when necessary in peripheral tissue and control the hepatic sinusoidal microcirculation by 
their contraction and relaxation. When liver injury occurs, they become activated and 
trans-differentiate into myofibroblastic cells, whose characteristics include the proliferation, loss of 
vitamin A droplets, expression of α-smooth muscle actin (α-SMA), secretion of profibrogenic 
mediators and ECM (Bataller and Brenner, 2001; Friedman, 2000). Therefore, controlling the 
population and activation of HSCs should be a potential therapeutic target against liver fibrosis. 
Interferons (IFNs) are cytokines with antiviral, immunomodulatory, and cell growth inhibitory 
effects. IFN-α and -β are classified as type I IFNs (Pestka et al., 1987; Uze et al., 2007), which are 
generally applied for the therapy of eradication of hepatitis B and C viruses. But studies using rodent 
models of hepatic fibrosis induced by chemical agents or diets suggested that IFNs have a 
antifibrotic potential independently of their antivirus activity (Chang et al., 2005; Fort et al., 1998; 
Inagaki et al., 2003; Tanabe et al., 2007). One of the targets of IFNs’ antifibrotic action is reported 
HSCs. For example, in vitro, IFN-α or -β is reported to suppress the α-SMA expression, the Col1a1 
and Col1a2 mRNA expression and proliferation in HSCs (Inagaki et al., 2003; Mallat et al., 1995; 
Ogawa et al., 2009; Rao et al., 2010; Shen et al., 2002). Although some of these effects appear to be 
mediated by the control of Smad4 and Smad7 expression and the interaction between 
phosphorylated STAT1 and p300, the detailed molecular mechanisms of these effects of IFNs remain 
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to be clarified. 
Recently, microRNAs (miRNAs), which are endogenous small non-coding RNA, have become a 
focus of interest as post-transcriptional regulators of gene expression through interaction with the 3’ 
untranslated region (3’UTR) of target mRNAs (Bartel, 2004). miRNAs are known to participate in 
cell proliferation, development, differentiation, and metabolism (Bartel, 2004). Moreover, it has been 
reported that expression of miRNAs could alter hepatic pathophysiology; miR-122 is involved in the 
IFN-β-related defense system against viral hepatitis C (Pedersen et al., 2007), and miR-26 is 
associated with survival and response to adjuvant IFN-α therapy in patients with hepatocellular 
carcinoma (HCC) (Ji et al., 2009a). Regarding HSCs, miR-15b and miR-16 are down-regulated upon 
HSC’s activation, and their overexpression induces apoptosis and a delay in the cell cycle (Guo et al., 
2009a; Guo et al., 2009b). Knockdown of miR-27a and miR-27b in activated HSCs allowed a switch 
to a more quiescent phenotype and decreased cell proliferation (Ji et al., 2009b). miR-150 and 
miR-194 suppress proliferation, activation, and ECM production of HSCs (Venugopal et al., 2010). 
Recently, it was reported that miR-29b was induced by IFN and suppressed type I collagen 
production in LX-2 cells (Ogawa et al., 2010).  
  In this study, the effect of miR-29b on other characteristics of HSCs, activation and proliferation, 
besides excess ECM production was examined to reveal the importance of miRNA mediated 
mechanism of IFN action. Furthermore, I identified miR-195 as a new type I IFNs-responsible 
miRNA and investigated the effect on the proliferation of HSCs. 
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Chapter I: Effect of miR-29b on the activation and proliferation 
of HSCs 
1. Introduction 
MicroRNAs participate in various biological phenomena, such as cell proliferation, development, 
differentiation, and metabolism (Bartel, 2004). miR-15, miR-16, miR-27, miR-150 and miR-194 has 
already proven to be player in the maintenance of HSCs functions (Guo et al., 2009a; Guo et al., 
2009b; Ji et al., 2009b; Venugopal et al., 2010). Previously, I showed that miR-29b was induced by 
interferon treatment and that it suppressed type I collagen production by modulating the Col1a1 and 
SP1 expression in the human HSC line LX-2 (Ogawa et al., 2010). Moreover, Roderburg et al. 
reported that miRNAs in the miR-29 family were significantly decreased in the fibrotic liver tissue 
of humans and mice (Roderburg et al., 2011). Thus, it has been speculated that the change in the 
expression of miR-29 is closely related to the development of liver fibrosis. Although analyses of 
miR-29 functions were performed on ECM metabolism in these reports, the cells used in these 
experiments were immortalized cell lines that had already been activated and had become 
myofibroblastic, which does not always reflect miR-29 function in quiescent HSCs in vivo. 
Therefore, it is important to evaluate the effect of miR-29 on the activation of primary-cultured 
HSCs. These cells are known to undergo spontaneous activation and trans-differentiation into 
myofibroblastic cells in culture, similarly to those in vivo. Activated HSCs express α-SMA and 
produce fibrogenic mediators, such as type I collagen and transforming growth factor-β (TGF-β). 
Here, I show the effects of miR-29b on the activation of HSCs using freshly isolated 
primary-cultured mouse HSCs. Overexpression of miR-29b suppressed cell viability and the 
expression of α-SMA. These effects seemed to be independent of the activation of focal adhesion 
kinase (FAK), extracellular signal-regulated kinase (ERK), and phosphatidylinositol-3 kinase 
(PI3K)–Akt, but were partially dependent on the reduction of c-fos mRNA. 
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2. Materials and methods 
2.1. Cells 
Primary HSCs were isolated from 12- to 16-week-old male C57BL/6N mice (Japan SLC Inc., 
Shizuoka, Japan) by pronase–collagenase digestion and subsequent purification by a single-step 
Nycodenz gradient, as previously described (Uyama et al., 2006). All animals received humane care, 
and the experimental protocol was approved by the Committee of Laboratory Animals according to 
institutional guidelines. Isolated HSCs were cultured on plastic dishes or glass chamber slides in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma Chemical Co., St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), 100 U/ ml 
penicillin, and 100 lg/ml streptomycin. The purity of cultures was evaluated by observation of the 
characteristic stellate cell shape using phase-contrast microscopy. 
The human HSC line LX-2 was donated by Dr. Scott L. Friedman (Mount Sinai School of 
Medicine, New York, NY, USA) (Xu et al., 2005). LX-2 cells were maintained in DMEM as 
described above.  
 
2.2. Transient transfection of a miR-29b precursor 
The miR-29b precursor (Ambion, Austin, TX, USA), which was a double-strand RNA mimicking 
the endogenous miR-29b precursor, and a negative control (Ambion, Austin, TX, USA) were 
transfected into mouse HSCs and LX-2 cells using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, 
CA, USA) at a final concentration of 10 nM in accordance with the manufacturer’s instructions. 
Briefly, the miRNA precursor and Lipofectamine RNAi-MAX were mixed at a ratio of 5 (pmol) : 1 
(μl) in Opti-MEM I Reduced Medium (Invitrogen, Carlsbad, CA, USA), incubated for 20 min at 
room temperature, and then added to the cultures. 
 
2.3. Quantitative real-time PCR 
Total RNA was extracted from cells using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). 
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Fifty nanograms of total RNA was reverse-transcribed to cDNA using the ReverTra Ace qPCR RT 
Kit (Toyobo, Osaka, Japan) in accordance with the manufacturer’s instructions. Gene expression was 
measured by real-time PCR using cDNA, SYBR Green real-time PCR Master Mix (Toyobo, Osaka, 
Japan), and a set of gene-specific oligonucleotide primers [alpha 1 (I) collagen (Col1a1): forward 
5’-CCTGGCAAAGACGGACTCAAC-3’, reverse 5’-GCTGAAGTCATAACCGCCACTG-3’; alpha 
2 (I) collagen (Col1a2): forward 5’-AAGGGTCCCTCTGGAGAACC-3’, reverse 
5’-TCTAGAGCCAGGGAGACCCA-3’; α-SMA: forward 
5’-TCCCTGGAGAAGAGCTACGAACT-3’, reverse 5’-AAGCGTTCGTTTCCAATGGT-3’; 
discoidin domain receptor (DDR) 2: forward 5’-CGAAAGCTTCCAGAGTTTGC-3’, reverse 
5’-GCTTCACAACACCACTGCAC-3’; fibronectin (FN) 1: forward 
5’-GATGCCGATCAGAAGTTTGG-3’, reverse 5’-GGTTGTGCAGATCTCCTCGT-3’; β1 integrin 
(ITGB1): forward 5’-CAACCACAACAGCTGCTTCTAA-3’, reverse 
5’-TCAGCCCTCTTGAATTTTAATGT-3’; platelet-derived growth factor receptor-β (PDGFR-β): 
forward 5’-GCGTATCTATATCTTTGTGCCAGA-3’, reverse 5’-ACAGGTCCTCGGAGTCCAT-3’; 
c-fos: forward 5’-AGAAGGGGCAAAGTAGAGCA-3’, reverse 5’-CAGCTCCCTCCTCCGATT-3’; 
c-jun: forward 5’-CCAGAAGATGGTGTGGTGTTT-3’, reverse 
5’-CTGACCCTCTCCCCTTGC-3’; glyceraldehyde-3-phosphate dehydrogenase (GAPDH): forward 
5’-TGCACCACCAACTGCTTAG-3’, reverse 5’-GGATGCAGGGATGATGTTC-3’] using an 
Applied Biosystems Prism 7500 (Applied Biosystems, Foster City, CA, USA). To detect miR-29b 
expression, the reverse transcription reaction was performed using a TaqMan microRNA Assay 
(Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer’s instructions. 
The expression level of GAPDH was used to normalize the relative abundance of mRNAs and 
miR-29b. 
 
2.4. Immunoblots 
Cells were lysed in RIPA buffer [50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% 
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sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] containing Protease Inhibitor Cocktail, 
Phosphatase Inhibitor Cocktail 1, and Phosphatase Inhibitor Cocktail 2 (Sigma). Proteins (2.5–10 
μg) were electrophoresed in a 5–20% gradient SDS–polyacrylamide gel (ATTO Co., Tokyo, Japan) 
and were then transferred onto Immobilon P membranes (Millipore, Bedford, MA, USA). After 
blocking, the membranes were incubated with primary antibodies [mouse monoclonal antibody 
against α-SMA (Dako, Ely, UK); rabbit polyclonal antibody against type I collagen (Rockland 
Immunochemicals, Inc., Gilbertsville, PA, USA); rabbit polyclonal antibodies against PDGFR-β and 
GAPDH (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); rabbit polyclonal antibodies 
against FAK and phospho-FAK (Y397) (Cell Signaling Technology Inc., Beverly, MA, USA); and 
mouse monoclonal antibodies against ERK, phospho-ERK (T202/Y204), Akt, and phospho-Akt 
(S473) (Cell Signaling Technology Inc., Beverly, MA, USA)] followed by peroxidase-conjugated 
secondary antibodies (Dako, Ely, UK). Immunoreactive bands were visualized by the enhanced 
chemiluminescence system (Amersham, Roosdaal, Netherlands) using a Fujifilm Image Reader 
LAS-3000 (Fuji Medical Systems, Stamford, CT, USA). 
 
2.5. F-actin staining 
HSCs on glass chamber slides were fixed in 4% paraformaldehyde in phosphate buffered saline 
(PBS) for 30 min and were permeabilized with 0.1% Triton X-100 in PBS for 5 min at room 
temperature. The nonspecific background signal was blocked with 1% bovine serum albumin (BSA) 
in PBS for 20 min. F-actin was stained with MFP488-phalloidin (Mobitec, Goettingen, Germany) in 
PBS with 1% BSA for 20 min. 40,6-diamidino-2-phenylindole (DAPI) (Dojindo Laboratories, 
Kumamoto, Japan) was used for counterstaining. 
 
2.6. Cell viability assay 
The cell viability was evaluated by the WST-1 assay based changes in absorbance at 450 nm. 
Freshly isolated mouse HSCs or LX-2 cells were plated in 96-well plates at a density of 1.5 × 10
4
 or 
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3 × 10
3
 cells/well, respectively. The following day, cells were transfected with the miR-29b 
precursor or a negative control as described above and were incubated for an additional 3 or 5 days 
before the assessment of cell viability. In another experiment, mouse HSCs that were transfected 
with the miR-29b precursor the day before were serum-starved overnight and then stimulated with 
PDGF-BB (10 ng/ml) (R&D Systems, Minneapolis, MO, USA). After incubation for 3 days, cell 
viability was assessed by the WST-1 assay. 
 
2.7. Statistical analysis 
Data presented as bar graphs are the means ± SD of at least three independent experiments. 
Statistical analysis was performed using the Student’s t-test, and P < 0.05 was considered to be 
statistically significant. 
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3. Results and discussion 
3.1. Expression of miR-29b in mouse HSCs during spontaneous activation 
At 1 day of culture after isolation, mouse HSCs adhered to plastic plates and exhibited round cell 
bodies with numerous lipid droplets similar to those observed in lipocytes (Fig. 1-1A). Cell bodies 
then began to gradually spread and flatten, increasing in size, and losing lipid droplets, resulting in 
the activated myofibroblastic phenotype (Fig. 1-1A). In addition to the changes in cell appearance, 
mRNA expression levels of α-SMA, Col1a1, Col1a2, FN1, DDR2, ITGB1, and PDGFR-β 
significantly increased at Days 4 and 7 of culture as compared to Day 1 (Fig. 1-1B). Immunoblot 
analyses confirmed the increases of type I collagen, α-SMA, and PDGFR-β protein levels at Days 4 
and 7 (Fig. 1-1C). These molecules have already been reported to be up-regulated in activated HSCs 
and involved in fibrosis (Friedman, 2000). Thus, the primary mouse HSCs used in this study were in 
an activated state. Although TGF-β1 is known as a key regulator of collagen production and fibrosis 
(Bessell et al., 2001), its mRNA expression level in mouse HSCs remained unchanged due to an 
unknown reason in this study (Fig. 1-1B). In contrast, miR-29b expression in mouse HSCs was 
significantly decreased to 28% and 32% at Days 4 and 7, respectively, as compared to Day 1 (Fig. 
1-1D). These findings raised the possibility that a reduction in miR-29b contributed to the 
up-regulation of the fibrosis-related genes listed above. 
 
3.2. Effects of miR-29b overexpression on the activation of HSCs 
To investigate this possibility, I next examined the effects of miR-29b overexpression on the 
activation of HSCs. Overexpression of miR-29b was achieved by the transient transfection of a 
synthesized miR-29b precursor, which was a double-strand RNA mimicking the endogenous 
miR-29b precursor. As shown in Fig. 1-2A, transfection of the miR-29b precursor markedly 
suppressed mRNA expression of Col1a1 and Col1a2 to 8% and 18%, respectively. Transfection 
significantly reduced mRNA expression of FN1 to 61% and also affected the expression of HSC 
activation-related molecules, such as α-SMA, DDR2, ITGB1, and PDGFR-β to 57%, 62%, 73%, and 
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42%, respectively. The TGF-β1 mRNA level was unaffected. At the protein level, expression of type 
I collagen, α-SMA, and PDGFR-β was suppressed by the overexpression of the miR-29b precursor 
(Fig. 1-2B). Col1a1, Col1a2, ITGB1, and PDGFR-β are predicted targets of miR-29b according to 
the miRNA target prediction databases TargetScan (http://www.targetscan.org/), miRBase 
(http://www. mirbase.org/), and mircrorna.org (http://www.microrna.org). Therefore, the suppression 
of these proteins might be due to the direct interaction of miR-29b with the 3’UTR of their 
corresponding mRNAs. Although α-SMA, DDR2, and FN1 are not predicted targets of miR-29b, 
their mRNA levels were suppressed. Thus, this effect was thought to be a secondary action of 
miR-29b over-expression. That is, it is suggested that miR-29b can not only target Col1a1, Col1a2, 
ITGB1, and PDGFR-β, but can also suppress the activation of HSCs by regulating other unidentified 
mechanisms, resulting in the suppression of α-SMA, DDR2, and FN1. In support of these results, 
morphological transformation from the quiescent to the myofibroblastic cell shape, as shown in Fig. 
1-1A, was impeded in miR-29b precursor-transfected cells (Fig. 1-2C); miR-29b 
precursor-transfected cells exhibited star-like morphology with small cell bodies and slender 
dendritic processes as compared to negative control-transfected cells at Day 4. Staining with 
MFP-phalloidin, which labels F-actin, also confirmed cytoskeletal changes in miR-29b 
precursor-transfected HSCs. Taken together, these results suggest that miR-29b is able to suppress 
HSC activation as well as ECM expression. 
 
3.3. Effect of miR-29b overexpression on number of HSCs 
Activated HSCs are known to acquire proliferation abilities (Friedman, 2000; Bataller and 
Brenner, 2001). I considered the possibility that miR-29b was able to regulate the number of HSCs. 
As shown by the WST-1 assay, when the miR-29b precursor was transfected into HSCs at Day 1, the 
cell number observed at Day 4 was significantly reduced to 88% of the negative control-transfected 
cells (Fig. 1-2D). Treatment of HSCs with 10 ng/mL PDGF-BB, a key mitogen for HSCs (Marra et 
al., 1995), significantly increased the cell number up to 1.7 times that of the non-treated cells (Fig. 
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1-2E), whereas overexpression of miR-29b inhibited this increase. Furthermore, in LX-2 cells, 
transfection of the miR-29b precursor decreased cell viability to 89% and 81% at 3 and 5 days 
following transfection, respectively (Fig. 1-2F). These results suggested that miR-29b is able to 
suppress the proliferation of HSCs and that down-regulation of miR-29b during HSC activation may 
contribute to their active proliferation.  
 
3.4. Effects of miR-29b overexpression on the ECM- and growth factor-related 
signaling in primary mouse HSCs 
The question of how miR-29b functions in blocking HSC activation was also examined. I showed 
that overexpression of miR-29b suppressed Col1a1, Col1a2, FN1, DDR2, ITGB1, and PDGFR-β 
expression (Fig. 1-2A and B). DDR2 is a receptor tyrosine kinase that is activated by the binding of 
collagen and was reported to be involved in the proliferation of HSCs and in the expression of 
matrix metalloproteinase-2 (Olaso et al., 2001, 2002). ITGB1 is a member of the integrin family and 
works as a FN or collagen receptor by forming a heterodimer with the integrin a subunit. ITGB1 is 
reported to be involved in the production of type I collagen and monocyte chemotactic protein-1 in 
HSCs (Marra et al., 1997; Wang et al., 2003). PDGFR-β is a receptor of PDGF and is involved in the 
proliferation of activated HSCs (Borkham-Kamphorst et al., 2004; Lechuga et al., 2006). Because it 
is known that intracellular signaling molecules such as FAK, ERK, and PI3K/Akt are key mediators 
for DDR2, ITGB1, and PDGFR-β (Marra et al., 1997; Carloni et al., 1997; Rodriguez-Juan et al., 
2009; Wu et al., 2010; Ikeda et al., 2002), their down-regulation by miR-29b may affect downstream 
signaling, resulting in the inhibition of both activation and proliferation of HSCs. To verify this 
hypothesis, I investigated the effect of miR-29b overexpression on the activation of FAK, Akt, and 
ERK. Activation of these kinases was evaluated by immunoblot analyses to detect the 
phosphorylation of each protein. Unexpectedly, phosphorylation of FAK, ERK, and Akt was 
unaffected by miR-29b overexpression (Fig. 1-3A). Next, I also examined the mRNA expression of 
c-fos and c-jun, which form the transcription factor AP-1 complex and are located downstream of 
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these signal kinases. Although transfection of the miR-29b precursor failed to alter c-jun expression, 
it significantly reduced c-fos mRNA expression to 55% (Fig. 1-3B). Because c-fos, but not c-jun is 
predicted target of miR-29b according to the above-mentioned miRNA target prediction databases, 
the direct interaction of miR-29b with the 3’ UTR of c-fos mRNA might lead to the suppression of 
c-fos expression. AP-1 is known to be one of the key transcription factors for the initiation of HSC 
activation (Gao et al., 2004; Poulos et al., 1997). So this fact indicates that effects of miR-29b may 
be partially mediated by c-fos downregulation. 
 
3.5. conclusion 
I confirmed that miR-29b expression decreased during HSC activation and found that 
overexpression of miR-29b is able to attenuate the activation, trans-differentiation and proliferation 
of HSCs although the precise molecular mechanism for this effect remains unknown. Changes in 
miR-29b expression seem to profoundly affect the activation of HSCs. 
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4. Figures  
Figure 1-1  Expression of miR-29b in mouse primary HSCs during culture. 
HSCs were isolated from mouse liver (Day 0) and cultured for the indicated periods. (A) 
Phase-contrast microscopy. Scale bar, 200 μm. (B) mRNA expression levels of Col1a1, Col1a2, 
α-SMA, DDR2, FN1, ITGB1, PDGFR-β and TGF-β1 were analyzed by real-time PCR. Results are 
expressed as relative expression against the expression on Day 1 of corresponding genes. 
*
P < 0.05, 
**
P < 0.01 compared with Day 1. (C) Protein expression levels of type I collagen, α-SMA and 
PDGFR-β were analyzed by Western blot. GAPDH served as an internal control. (D) miR-29b 
expression level was analyzed by real-time PCR. 
*
P < 0.05, 
**
P < 0.01 compared with Day 1. 
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Figure 1-2  Effects of miR-29b overexpression on the activation of HSCs. 
(A–D) Mouse HSCs were transfected with 10 nM miR-29b precursor or a negative control (control) 
on Day 1 and incubated for 3 days. (A) mRNA expression levels of Col1a1, Col1a2, α-SMA, DDR2, 
FN1, ITGB1, PDGFR-β and TGF-β1 were analyzed by real-time PCR. The results are expressed as 
relative expression against the expression of untreated control. 
*
P < 0.05, 
**
P < 0.01 compared with 
control. (B) Protein expression levels of type I collagen, α-SMA and PDGFR-β were analyzed by 
Western blot. GAPDH served as an internal control. The right graph indicates the average of the 
densitometric results of n = 2. (C) Phase-contrast microscopy (upper) and MFP488-phalloidin 
staining for F-actin (lower). Scale bar, 100 μm. (D) Cell viability was evaluated by WST-1 assay. 
**
P 
< 0.01 compared with control. (E) Mouse HSCs were transfected with miR-29b precursor or a 
negative control (control) on Day 1. Twenty-four hours later, cells were serum-starved overnight, 
stimulated with or without PDGF-BB (10 ng/ml) and incubated for an additional 3 days. In Day 6, 
cell viability was evaluated by WST-1 assay. 
**
P < 0.01 compared with control plus PDGF-BB. 
†
P < 
0.05 compared with control plus non-treat. (F) LX-2 cells were transfected with miR-29b precursor 
or a negative control (control) and incubated for the indicated periods. Cell viability was evaluated 
by WST-1 assay. *P < 0.05, **P < 0.01 compared with the control. 
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Figure 1-3  Effects of miR-29b overexpression on the ECM- and growth factor-related 
signaling in mouse primary HSCs. 
Mouse HSCs were transfected with 10 nM miR-29b precursor or a negative control (control) on Day 
1 and were incubated for 3 days. (A) Phosphorylation of FAK (Y397), ERK (T202/Y204) and Akt 
(S473) was analyzed by Western blot. (B) mRNA expression levels of c-fos and c-jun were analyzed 
by real-time PCR. The results are expressed as relative expression against the expression of control. 
*
P < 0.05 compared with control. 
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Chapter II: miR-195-mediated effect of IFN on the proliferation of 
HSCs 
1. Introduction 
Some of recent studies indicated that type I interferons (IFNs) have direct effects on hepatic 
stellate cells (HSCs) and that these effects contribute antifibrotic actions against hepatic fibrosis. For 
example, in vitro, IFN-α or -β is reported to suppress proliferation in HSCs (Mallat et al., 1995; Rao 
et al., 2010; Shen et al., 2002). Active proliferation is one of the characteristics of activated HSCs, 
which have been recognized as major player in pathogeneses of hepatic fibrosis. Therefore, 
controlling the population of HSCs should be one of the potential therapeutic strategies against liver 
fibrosis. Recently the number of reports about involvement of miRNA, such as miR-15, miR-16, 
miR-27, miR-150 and miR-194, in the proliferation of HSCs has been increased (Guo et al., 2009a; 
Guo et al., 2009b; Ji et al., 2009b; Venugopal et al., 2010). Because over 1000 miRNA have been 
identified in human cells, other miRNAs may participate in the regulation of HSC’s functions. 
In the present study, I measured the levels of miR-195 in primary-cultured mouse HSCs and found 
that its expression was markedly reduced in their activation phase, suggesting the regulatory role of 
miR-195 in the activation/deactivation process of HSCs. Previously, there was no report about the 
relationship between miR-195 and the function of HSCs. But miR-195 is categorized into the same 
family as miR-15b and miR-16 which has been reported to be down-regulated upon HSC’s 
activation, and their overexpression induces apoptosis and a delay in the cell cycle (Guo et al., 
2009a; Guo et al., 2009b). Furthermore, in human hepatocellular carcinoma cells, miR-195 has been 
reported to regulate cell cycle by targeting E2F3, CDK6, and cyclin D1 (Xu et al., 2009). So, I 
examined the involvement of miR-195 in the proliferation of HSC and in type I IFN, in particular 
IFN-β, -induced inhibition of their growth. 
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2. Materials and methods 
2.1. Materials 
Necessary reagents and materials were obtained from the following sources: Dulbecco’s modified 
Eagle’s medium (DMEM) from Sigma Chemical Co. (St. Louis, MO, USA); fetal bovine serum 
(FBS) from Invitrogen (Carlsbad, CA, USA); human natural IFN-α and IFN-β from Otsuka 
Pharmaceutical Co. (Tokushima, Japan) and Toray Industries Inc. (Tokyo, Japan), respectively; 
precursor and inhibitor of miR-195, and the corresponding negative controls from Ambion (Austin, 
TX, USA); mouse monoclonal antibody against cyclin E1, cyclin D1 and p21, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from MBL (Nagoya, Japan), Cell Signaling 
Technology Inc. (Beverly, MA, USA), and Chemicon International Inc. (Temecula, CA, USA), 
respectively; rabbit polyclonal antibodies against cyclin-dependent kinase (CDK) 6 and E2F3 from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA); goat polyclonal antibody against CDK4 
from Santa Cruz Biotechnology Inc.; enhanced Chemiluminescence plus detection reagent from GE 
Healthcare (Buckinghamshire, UK); Immobilon P membranes from Millipore Corp. (Bedford, MA, 
USA); reagents for cDNA synthesis and real-time PCR from Toyobo (Osaka, Japan); a cell counting 
kit from Dojindo Laboratories (Kumamoto, Japan); and all other reagents from Sigma Chemical Co. 
or Wako Pure Chemical Co. (Osaka, Japan). 
 
2.2. Cells 
Human hepatic stellate cell line LX-2 was donated by Dr. Scott L. Friedman (Mount Sinai School 
of Medicine, New York, NY, USA) (Xu et al., 2005). LX-2 cells were maintained in DMEM 
supplemented with 10% FBS (DMEM/FBS) and were plated at a density of 0.7–1.5 × 10
4
 cells/cm
2
 
24 h prior to biological assay. Biological assays were done in DMEM/FBS unless stated otherwise. 
Mouse primary HSCs were isolated from male C57BL/6 mice by the pronase-collagenase digestion 
method as described previously (Uyama et al., 2006) and were cultured in DMEM/FBS. 
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2.3. Transient transfection of miRNA precursors and inhibitors 
Precursor of miR-195, which was a double-strand RNA mimicking endogenous miR-195 
precursor, and the negative control with a scrambled sequence were transfected into LX-2 cells using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at a final concentration of 50 nM in 
accordance with the manufacturer’s instructions. Briefly, miRNA precursor and Lipofectamine 2000 
were mixed at a ratio of 25 (pmol) : 1 (μl) in Opti-MEM I Reduced Medium (Invitrogen, Carlsbad, 
CA, USA), incubated for 20 min at room temperature, and were then added to the cultures. After 24 
h, the culture medium was replaced with fresh medium. Inhibitor of miR-195, which was designed to 
bind to endogenous miR-195 and inhibit its activity, and the negative control with a scrambled 
sequence were transfected similarly. After 6 h, the culture medium was changed and IFN-β was 
added successively. 
 
2.4. Cell proliferation assay 
LX-2 cells were plated at a density of 2 × 10
3
 cells/well in 96-well plates 24 h prior to 
experiments. The culture medium was replaced by fresh medium containing different concentrations 
of IFNs at day 0 and 3. After 3, 5, and 7 days of treatment, cell proliferation was measured by 
WST-1 assay. In another experiment, the cells were plated at a density of 3 × 10
3
 cells/well in 
96-well plate for 24 h prior and were then transfected with the miR-195 precursor as described above. 
After 24 h, the medium was changed and the culture was continued for an additional 1–3 days before 
the measurement of cell proliferation. 
 
2.5. Cell cycle analysis 
Cells were serum starved for 24 h and then the medium was replaced with IFN-containing 
DMEM/FBS. At the indicated time points after treatment, the cells were harvested by trypsinization, 
washed in phosphate buffered saline (PBS), and fixed in ice-cold 70% ethanol. The cells were 
washed in PBS and resuspended in PBS containing 500 μg/ml RNase A and incubated for 20 min. 
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Cellular DNA was stained with propidium iodide at a final concentration of 25 μg/ml for 20 min. 
The cells were analyzed using a FACSCalibur HG flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ, USA). A total of 20,000 events were counted for each sample. Data were analyzed using 
ModFIT LT software (Verity Software House, Topsham, ME, USA). 
 
2.6. Quantitative real-time PCR 
 Quantitative real-time PCR was performed according to the method described elsewhere with use 
of a set of gene-specific oligonucleotide primers (Table 2-1) using an Applied Biosystems Prism 
7500 (Applied Biosystems, Foster City, CA, USA) (Ogawa et al., 2010). To detect miR-195 
expression, the reverse transcription reaction was performed using a TaqMan microRNA Assay 
(Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer’s instructions. 
The expression level of GAPDH was used to normalize the relative abundance of mRNAs and 
miR-195. 
 
2.7. Immunoblotting 
 Cells were lysed in RIPA buffer [50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] containing Protease Inhibitor Cocktail, 
Phosphatase Inhibitors Cocktail 1, and Phosphatase Inhibitor Cocktail 2 (Sigma Chemical Co., St. 
Louis, MO, USA). Proteins (20 μg) were electrophoresed in a 10% SDS-polyacrylamide gel and 
then transferred onto Immobilon P membranes (Ogawa et al., 2010). Immunoreactive bands were 
visualized by the enhanced chemiluminescence system using a Fujifilm Image Reader LAS-3000 
(Fuji Medical Systems, Stamford, CT, USA). 
 
2.8. Luciferase reporter assay 
 Interaction of miR-195 to the 3’UTR of the cyclin E1 gene was tested according to the reported 
method (Ogawa et al., 2010). The 3’UTR of the cyclin E1 gene containing putative miR-195 target 
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regions was obtained by PCR using cDNA derived from LX-2 and a primer set listed in Table 2-1. 
The obtained DNA fragments (497 bp) were inserted into a pmirGLO Vector (Promega, San Luis 
Obispo, CA, USA). LX-2 cells, plated in 96-well plates at a density of 2 × 10
4
 cells/well 24 h prior 
to experiment, were transfected with 200 ng of reporter plasmid and miRNA precursor using 
Lipofectamine 2000. After 24 h, the medium was changed to 20 μl of PBS. The Dual-Glo Luciferase 
Assay System (Promega, San Luis Obispo, CA, USA) was used to analyze luciferase expression in 
accordance with the manufacturer’s protocol. Firefly luciferase activity was normalized to Renilla 
luciferase activity to adjust for variations in transfection efficiency among experiments. 
 
2.9. Statistical analysis 
 Data presented as graphs are the means ± S.D. of at least three independent experiments. 
Statistical analysis was performed using Student’s t-test. P < 0.05 was considered significant. 
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3. Results 
3.1. Reduction of miR-195 expression during activation of primary-cultured HSCs 
It has been known that, when maintained in a plastic culture plate, freshly isolated 
primary-cultured HSCs undergo spontaneous activation and transformation into myofibroblastic 
cells that express α-SMA and produce fibrogenic mediators, such as type I collagen and transforming 
growth factor-β. In my preliminary experiments using primary-cultured mouse HSCs, I noticed that 
the cells drastically decreased the expression of miR-195 when they underwent spontaneous 
activation (unpublished observation). The present study confirmed this notion as shown in Figure 
2-1A. miR-195 expression level certainly decreased in activation process of primary-cultured mouse 
HSCs. In contrast, the expression levels of α-SMA and cyclin E1 mRNA increased (Fig. 2-1B). 
Accordingly, I considered that miR-195 plays a role as an antiproliferative and antiactivating miRNA 
in HSCs. As a matter of fact, there was a study showing that miR-16 family including miR-195 
inhibits proliferation of lung cancer cells by silencing cyclins D1 and E1, and CDK6 (Liu et al., 
2008). The result indicated by Figure 2-1 and the cited study together drove me to explore the IFN’s 
antiproliferative action on HSCs (Mallat et al., 1995; Shen et al., 2002), focusing on miR-195 and 
cell cycle-related genes. 
 
3.2. Effects of IFN-α and -β on proliferation of HSCs 
First, I investigated the effects of type I IFNs on the proliferation of LX-2 cells using a WST-1 
assay. LX-2 cells in control culture continued to grow during the experimental period of 7 days (Fig. 
2-1C). IFN-α and -β both, but the latter more actively, decreased cell proliferation time-dependently 
at a concentration of 1,000 IU/ml, supporting the previous studies (Mallat et al., 1995; Shen et al., 
2002). Dose-dependency of the growth inhibition is shown in IFN concentrations from 10 to 1,000 
IU/ml (Fig. 1D). 
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3.3. Effects of IFN-α and -β on cell cycle distribution 
To elucidate the mechanism of the growth inhibitory effect of IFN, I next examined the change in 
cell cycle distribution in response to IFN-α and -β treatment by flow cytometry. LX-2 cells were 
synchronized in G0/G1 phase by serum starvation for 24 h. In non-treated cells (control), population 
in G0/G1 phase was reduced after serum exposure, which was accompanied by the increase of 
population in S phase. This cell cycle transition peaked at 24 h (Fig. 2-2, upper part). In cells treated 
with IFN-α or -β, the G0/G1 phase population was larger and the S phase population was smaller 
than in the control cells at 15 h and 24 h. In addition, the accumulation of cells in early S phase was 
observed at 32 h (Fig. 2-2, middle and lower parts). These delays in cell cycle shift were more potent 
in IFN-β-treated cells than in IFN-α-treated cells. It was concluded that type I IFN hampered HSC 
proliferation through a delay in the cell cycle at the transition from G1 to S phase and in the 
progression of S phase. 
 
3.4. Regulation of cyclin E1 and p21 expression by IFN-β 
IFN-β was chosen in the following experiments because of its more potent inhibition of cell cycle 
progression than IFN-α as described above. The transition from G1 to S phase and the progression of 
S phase are known to be influenced by various regulators (Golias et al., 2004). Among them, I found 
that IFN-β significantly decreased cyclin E1 mRNAexpression levels by 0.6- to 0.7-fold at 6 and 24 
h and increased p21 mRNA expression levels by 1.4- to 2.3-fold at 6, 24, 48, and 72 h in LX-2 cells 
(Fig. 2-3). The expression levels of CDK4 and CDK6 were also reduced by IFN-β at early phase 
with less extent. The others showed negligible change within 24 h although variable dynamics were 
seen thereafter; changes of cyclin D1, CDK2, and p27 expression at late phase were toward cell 
cycle promotion with currently unknown reason. 
 
3.5. Regulation of miR-195 expression by IFN-β 
The results indicated from Figure 2-1 strongly suggested the possibility that IFN-β increase the 
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expression of miR-195 in LX-2 cells. To test this possibility, I examined the expression levels of 
miR-195 in IFN-β-treated LX-2 cells. As a result, the miR-195 expression level was significantly 
increased by IFN-β treatment at 24, 48, and 72 h (Fig. 2-4A). 
 
3.6. Regulation of cyclin E1 and p21 expression by miR-195 
The results obtained from experiments shown in Figures 2-3 and 2-4A led me to hypothesize that 
IFN-β up-regulates the expression of miR-195, which then down-regulates the expression of cyclin 
E1 and up-regulates the expression of p21. In addition, there had been a study reporting that 
miR-195 targets E2F3, CDK6, and cyclin D1 in addition to cyclin E1 (Xu et al., 2009). Under these 
considerations, I examined the changes in the expression levels of the above-mentioned cell 
cycle-related molecules and CDK4 by introducing miR-195 precursor into LX-2 cells. Transfection 
of miR-195 precursor increased the miR-195 expression levels in LX-2 cells by up to 10,000–30,000 
times compared with those in cells transfected with negative control (data not shown). Cyclin E1 
mRNA and protein expression levels showed a remarkable reduction up to 72 h as result of miR-195 
overexpression (Fig. 2-4B, C). On the other hand, p21 mRNA and protein expression levels showed 
a marked increase. CDK4, CDK6, and cyclin D1 expression levels were significantly changed at the 
mRNA level, but negligibly at the protein level. E2F3 mRNA and protein expression levels were 
unchanged (Fig. 2-4B, C). These results suggested that miR-195 mainly regulated cyclin E1 and p21 
expression in LX-2 cells. Moreover, transfection of miR-195 precursor (50 nM) decreased the 
proliferation of LX-2 cells in the WST-1 assay (Fig. 2-4D). These results showed that miR-195 
down-regulates endogenous cyclin E1 expression and upregulates p21 expression, resulting in the 
attenuation of cell cycle progression and cell proliferation. 
 
3.7. Interaction of miR-195 with cyclin E1 3’UTR in LX-2 cells 
Next, I examined whether miR-195 interacted directly with cyclin E1 3’UTR in LX-2 cells. The 
predicted miRNA target sites for miR-195 in the cyclin E1 3’UTR were analyzed using TargetScan 
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Human Release 5.1 (http://www.targetscan.org/). The cyclin E1 3’UTR contained two target sites for 
miR-195 (Fig. 2-5A, B). To investigate the direct interaction between them, the part of the cyclin E1 
3’UTR containing the two miR-195 target sites (497 bp) was cloned from LX-2 cells, inserted the 
downstream of a firefly luciferase reporter gene in a pmirGLO vector (Fig. 2-5C), and cotransfected 
into LX-2 cells. As shown in Figure 2-5D, luciferase reporter activity decreased significantly in 
miR-195 precursor-transfected cells compared with cells transfected with a negative control of the 
precursor. These results suggested a direct interaction between miR-195 and cyclin E1 3’UTR in 
LX-2 cells. Binding site of miR-195 was not found in p21 3’UTR by TargetScan. 
 
3.8. Regulation of cyclin E1 expression by IFN-β and miR-195 
To confirm the contribution of miR-195 to the inhibitory effect of IFN-β on cyclin E1 expression, 
LX-2 cells were first transfected with 50 nM miR-195 inhibitor and then treated with 1,000 IU/ml 
IFN-β. As shown in Figure 2-6A, miR-195 inhibitor blocked the inhibitory effect of IFN-β on cyclin 
E1 mRNA expression at 16 and 24 h. Although there was no difference in the cyclin E1 mRNA 
expression between IFN-β-treated cells and non-treated cells (control) at 48 h, the cyclin E1 mRNA 
expression level in miR-195 inhibitor plus IFN-β-treated cells was up-regulated compared with 
non-treated cells (Fig. 2-6A). Immunoblot analysis revealed that miR-195 inhibitor elevated the 
cyclin E1 expression level of IFN-β-treated cells at 24 and 48 h (Fig. 2-6B). 
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4. Discussion 
In this study, I showed that IFN-β is more antiproliferative on LX-2 cells than IFN-α, which 
appears to be contradictory to their known mechanism of action: both IFN-α and -β exert their 
activities through the common signaling pathway, beginning with binding to the same type I IFN 
receptor (IFNAR) consisting of IFNAR1 and IFNAR2, which activate the common components of 
janus kinase/signal transducer and activator of transcription (STAT) pathway (Darnell et al., 1994). 
However, a similar activity difference between the IFNs has also been demonstrated in colon cancer 
cell lines (Katayama et al., 2007) and in rat HSCs (Shen et al., 2002). Some studies showed that 
IFN-β but not IFN-α formed a stable complex with IFNARs, suggesting that IFN-β may interact with 
IFNAR chains in a manner different from IFN-α (Croze et al., 1996; Russell-Harde et al., 1999). 
I showed here that IFN-β down-regulated the expression of cyclin E1 and up-regulated the 
expression of p21, which caused the cells to be less active proceeding in the transition from G0 to 
G1 phase and in the progression of S phase. The cell cycle is regulated by various molecules, such as 
cyclins and CDKs. Cyclin E is essential in activating CDK2. The cyclin E-CDK2 complex 
phosphorylates pRb at G1 phase, leading to gene transcription activities that are needed in S phase, 
and also activates the factors involved in DNA replication at early S phase (Golias et al., 2004). It 
has been reported that cyclin E1 expression increased in non-parenchymal cells of human fibrotic 
liver and that cyclin E1-deficient mice developed milder liver fibrosis compared with wild-type mice 
after CCl4 administration (Nevzorova et al., 2010). These results imply that cyclin E1 regulates the 
progression of liver fibrosis by accelerating HSC proliferation. 
The most frequent miRNAs that targets cyclin E1 are the miR-16 family, which consists of 
miR-15, -16, -195, -424, and -497 (Liu et al., 2008; Wang et al., 2009). I here observed the induction 
of miR-195 by IFN-β. miR-195 was reported to be down-regulated in human HCC tissues and to 
suppress HCC growth through the targeted interference of cyclin D1, CDK6, and E2F3 in a 
xenograft mouse model (Xu et al., 2009), while it was reported to target cyclin E1 in addition to the 
above-mentioned factors in A549 cells (Liu et al., 2008). miR-15b and miR-16 are down-regulated 
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concomitantly with HSC activation and their overexpression induces apoptosis and a delay of cell 
cycle in HSCs by targeting Bcl-2 and cyclin D1 (Guo et al., 2009a,b). However, the role of miR-195 
in HSCs remains unknown. I showed here that miR-195 expression was decreased during 
spontaneous activation of primary-cultured mouse HSCs and that miR-195 interacted with cyclin E1 
3’UTR and lowered the expression levels of the cyclin E1 mRNA and protein in LX-2 cells. These 
results suggest that the downregulation of miR-195 may associate with the proliferation of HSCs in 
fibrotic liver similarly to miR-15 and miR-16. In this study, the changes of the protein expression 
levels of E2F3, CDK6, and cyclin D1, which were reported to be regulated by miR-195 (Xu et al., 
2009), were negligible by miR-195, although the exact reason for this phenomenon was not 
determined. However, because the total context scores obtained by TargetScan were―0.73 for cyclin 
E1, ―0.33 for E2F3, ―0.32 for cyclin D1, and ―0.09 for CDK6, the result obtained here was 
thought to be reasonable. In addition, minimal or negligible effect of miR-195 on the expression of 
E2F3, CDK4, CDK6, and cyclin D1 was compatible with that of IFN-β on these factors. 
Furthermore, inhibition of miR-195 by miR-195 inhibitor attenuated the effect of IFN-β on cyclin E1 
expression, though not so strong. Taken together, it is most likely that the downregulation of cyclin 
E1 by IFN-β treatment in HSCs is mediated through miR-195 up-regulation. The mechanism 
through which IFN-β induces miR-195 in LX-2 cells need to be explored further. 
It is well known that IFNs induce the expression of p21 in various cancer cells (Sangfelt et al., 
1999; Katayama et al., 2007). I also observed the up-regulation of p21 in IFN-β-treated cells. 
Therefore, p21, in addition to cyclin E1, may play a role in IFN-induced growth inhibition of HSCs. 
Until now, it has been reported that IFNs induce p21 expression through the binding of STAT and 
IFN regulatory factor, which are critical signaling molecules after IFN-IFNAR interaction, to p21 
gene promoter (Gartel and Tyner, 1999). Unexpectedly, I found the upregulation of p21 by miR-195 
(Fig. 2-4). The results obtained here raise a new possibility that the up-regulation of p21 by IFN-β in 
HSCs may be partially mediated through miR-195. 
In conclusion, type I IFN, in particular IFN-β, inhibited the proliferation of human HSCs by 
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delaying the cell cycle in G1 to early S phase through the down-regulation of cyclin E1 and 
up-regulation of p21. The cyclin E1 down-regulation and p21 up-regulation were partially mediated 
by miR-195 that was up-regulated by IFN-β. This study raises a new mechanistic aspect of the 
antifibrotic effect of IFN in liver fibrosis and the possibility of influencing miR-195 as a therapeutic 
strategy for liver fibrosis. 
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5. Table 
Table 2-1. Sequences of primers used in real-time PCR analyses and 3’UTR cloning for 
luciferase reporter assay 
Gene Accession No. Sequence 
real-time PCR   
CDK6 NM_001259 Forward: 5'-ATATCTGCCTACAGTGCCCTGTCTC-3' 
  Reverse: 5'-GTGGGAATCCAGGTTTTCTTTGCAC-3' 
Cyclin E1  NM_001238 Forward: 5'-GCAGTATCCCCAGCAAATC-3' 
  Reverse: 5'-TCAAGGCAGTCAACATCCA-3' 
Cyclin D1  NM_053056 Forward: 5'-GCTGTGCATCTACACCGACAACTC-3' 
  Reverse: 5'-AGGTTCCACTTGAGCTTGTTCACC-3' 
E2F3 NM_001949 Forward: 5'-CCAACTCAGGACATAGCGATTGCTC-3' 
  Reverse: 5'-AGGAATTTGGTCCTCAGTCTGCTGT-3' 
GAPDH NM_002046 Forward: 5'-GCACCGTCAAGGCTGAGAAC-3' 
  Reverse: 5'-TGGTGAAGACGCCAGTGGA-3' 
p21 NM_000389 Forward: 5'-AGCAGAGGAAGACCATGTGGA-3' 
  Reverse: 5'-GGAGTGGTAGAAATCTGTCATGCT-3' 
3'UTR cloning   
Cyclin E1 NM_001238 Forward: 5'-TTCTCGAGATCCTTCTCCACCAAAGACAGTT-3' 
  Reverse: 5'-TTTCTAGAGAATGGATAGATATAGCAGCACTTACA-3' 
The forward and reverse primers for 3’UTR cloning carried the XhoI and XbaI sites at 
their 5’-ends, respectively. 
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6. Figures 
Figure 2-1  Expression of miR-195 in mouse HSCs during primary culture and growth 
inhibitory effect of IFN-α and -β on human stellate cells. 
(A), (B) Isolated mouse HSCs were cultured for the indicated periods. The expression levels of 
miR-195 (A), and α-SMA and cyclin E1 mRNA (B) were measured by real-time PCR. 
*
P < 0.05, 
**
P 
< 0.01 compared with 1 day. (C), (D) LX-2 cells were incubated with IFN-α or -β (1,000 IU/ml) for 
3–7 days (C), or with IFN-α or -β at the concentration of 10–1,000 IU/ml for 7 days (D). Control 
indicates non-treated cells. The proportion of viable cells was determined using a WST-1 assay. 
**
P 
< 0.01 compared with control. 
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Figure 2-2  Effect of IFN-α and -β on cell cycle distribution in human stellate cells. 
LX-2 cells synchronized in G0/G1 phase were then incubated with IFN-α or -β (1,000 IU/ml) in 
DMEM/FBS for the indicated periods. Control indicates non-treated cells. The cell cycle was 
analyzed by flow cytometry. The left black, shaded and right black region indicates the histogram 
measured by flowcytometry, G0/G1 phase (left), S phase and G2/M phase respectively, as analyzed 
by ModFIT LT software. 
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Figure 2-3  Expression of cell cycle-related genes in stellate cells. 
LX-2 cells were incubated with IFN-β (1,000 IU/ml) for up to 72 h for determining the expression 
levels of mRNAs of cyclin D1, cyclin E1, CDK2, CDK4, CDK6, p21, and p27. Control indicates 
non-treated cells. 
*
P < 0.05, 
**
P < 0.01 compared with control. 
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Figure 2-4  Regulation of expression of cell cycle regulators by miR-195. 
(A) LX-2 cells were incubated with IFN-β (1,000 IU/ml) for up to 72 h for determining the 
expression levels of miR-195. Control indicates non-treated cells. 
*
P < 0.05, 
**
P < 0.01 compared 
with control. (B–D) LX-2 cells were transfected with 50 nM miR-195 precursor or a negative control 
(control). (B) mRNA expression levels of E2F3, CDK4, CDK6, cyclin D1, cyclin E1, and p21 
measured at 24, 48, 72, and 96 h post-transfection. (C) Protein expression of E2F3, CDK4, CDK6, 
cyclinD1, cyclinE1, and p21 examined at 48, 72, and 96 h post-transfection. (D) Growth of LX-2 
cells transfected with 50 nM miR-195 precursor or a negative control (control) was measured using a 
WST-1 assay. 
*
P < 0.05, 
**
P < 0.01 compared with control. 
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Figure 2-5  Interaction of miR-195 with the 3’UTR of cyclin E1 mRNA. 
(A) Schematic indication of the putative miR-195 target sites in the 3’UTR of the cyclin E1 mRNA. 
Tested sequences indicate the regions that were inserted into the luciferase reporter vector. (B) 
Predicted pairing of the target region and miRNAs. (C) Structure of the luciferase reporter vector 
(Ogawa et al., 2010). The putative miR-195 target region in cyclin E1 3’UTR (tested sequence) was 
ligated into the MCS. Arrows indicate the gene directions. AmpR indicates an ampicillin resistance 
gene. (D) Reporter gene assay of the interaction between the 3’UTR of cyclin E1 mRNA and 
miR-195 in LX-2 cells. Results are expressed as the relative activities against the activity in the 
presence of the control. 
*
P < 0.05, 
**
P < 0.01 compared with control. 
 
 
  
40 
 
Figure 2-6  Regulation of cyclin E1 expression by IFN-β and miR-195. 
LX-2 cells were transfected with 50 nM miR-195 inhibitor or a negative control. After 6 h, the 
culture medium was changed and then IFN-β (1,000 IU/ml) was added. Cells were then incubated 
for the indicated time periods. (A) mRNA expression levels of cyclin E1. (B) Protein expression 
levels of cyclin E1. GAPDH are for loading adjustment. Control; cells were transfected with a 
negative control and incubated without IFN-β. 
*
P < 0.05, 
**
P < 0.01. 
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General Discussion 
HSCs are considered as major player in hepatic fibrosis because they undergo a 
trans-differentiation into myofibroblastic cells termed “activation’’ in response to fibrogenic stimuli 
and produce excessive ECMs. The characteristics of activated HSCs also include the active 
proliferation (Friedman, 2000; Bataller and Brenner, 2001). Type I IFNs were shown to have direct 
action on HSCs and suppress the activation, proliferation and production of ECM of HSCs. Although 
some of these effects appear to be mediated by the control of Smad4 and Smad7 expression and the 
interaction between phosphorylated STAT1 and p300 (Gartel et al., 1999; Inagaki et al., 2003; Rao et 
al., 2010), the detailed molecular mechanisms of these effects of type I IFNs remain to be clarified. 
Therefore, examining the unknown mechanisms of effects of type I IFNs for HSCs contribute to the 
understanding the HSCs functions and give the possibility of new therapeutic approach for hepatic 
fibrosis. In this study, I tried to reveal the miRNAs-mediated action mechanisms of type I IFNs for 
HSCs. 
It has been reported that miR-29b was induced by IFN and suppressed type I collagen production 
in LX-2 cells (Ogawa et al., 2010). So, I especially focused on miRNAs. Gain of function 
experiments showed that miR-29b is involved in all examined characteristics of HSCs, namely 
activation, excess ECM production and proliferation for the first time. I also identified miR-195 as a 
new IFN-responsible miRNA in HSCs and shows that miR-195 mediated the inhibitory effect of IFN 
in HSCs proliferation. miR-195 seemed to have no involvement in activation and excess ECM 
production (unpublished data). Thus, it is suggested that there are differences among miRNAs in the 
event and the degree of involvement. Moreover, because over 1000 miRNA have been identified in 
human cells, other miRNA in addition to miR-29b and miR-195 may mediate the IFN’s action in 
HSCs.   
The findings in this study also raise the possibility of miR-29b and miR-195 as a new therapeutic 
target for hepatic fibrosis. In fact, miR-29 family (miR-29a, -29b and -29c) have been further 
investigated about the role in HSCs function, hepatic and other organ fibrosis (Kwiecinski et al., 
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2012; Zhang et al., 2015) and now it is defined as a one of “fibromiR”. More recently, it was 
reported that gene transfer of miR-29b to liver prevented CCl4-induced hepatic fibrosis in mouse 
(Wang et al., 2014). Although the therapeutic effect of miR-195 itself in hepatic fibrosis isn’t shown, 
cyclin E1, proved to be a target of miR-195 in HSCs in this study, has reported to be essential to 
liver fibrogenesis in mouse (Nevzorova et al., 2010; Nevzorova et al., 2012). So, strategies inducing 
sufficient amounts of miR-195 in HSCs may achieve prevention of hepatic fibrosis progression. 
In conclusion, these observations reveal miR-29b and miR-195-mediated new action mechanisms 
of type I IFNs for HSCs. 
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